Stockscreener 앱 받기
0.00
100.00%
-14.49
시간 외 거래:
14.49
14.49
+
전일 마감가:
$14.49
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$4.55B
수익:
$634.21M
순이익/손실:
$-27.11M
주가수익비율:
0.00
EPS:
-0.0885
순현금흐름:
$29.85M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$14.50
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
0.00 | 4.55B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-29 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-18 | 업그레이드 | Needham | Hold → Buy |
| 2025-07-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
MSN Money - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Glazer Capital (FOLD) reports zero holdings after falling below 5% stake - Stock Titan
MSN - MSN
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
Amicus Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Vanguard Capital Management holds 5.20% of Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Global BMI Index - marketscreener.com
Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
BioMarin closes $4.8bn Amicus deal to expand rare disease portfolio - MSN
Net current asset value per share of Amicus Therapeutics, Inc. – BIVA:FOLD - TradingView
Amicus Therapeutics Hits New 52-Week High at $14.50 - Markets Mojo
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from Russell 3000E Growth Index - marketscreener.com
Amicus Therapeutics (NASDAQ: FOLD) director’s shares and options cashed out in BioMarin deal - Stock Titan
Amicus Therapeutics (FOLD) director cashes out stock and options in BioMarin deal - Stock Titan
BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director cashes out equity in BioMarin deal - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director equity paid out at $14.50 in BioMarin deal - Stock Titan
Director at Amicus (NASDAQ: FOLD) exits stake in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays out Amicus (NASDAQ: FOLD) director - Stock Titan
BioMarin acquisition cashes out Amicus (FOLD) director’s shares and options - Stock Titan
Amicus Therapeutics (FOLD) CAO exits stock and options in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays CDO Castelli (FOLD) $14.50 per share - Stock Titan
Amicus Therapeutics (FOLD) CPO equity fully cashed out at $14.50 deal price - Stock Titan
Amicus (FOLD) chief legal officer exits equity as BioMarin buyout pays $14.50 - Stock Titan
Amicus Therapeutics (FOLD) CFO exits equity as BioMarin acquisition closes - Stock Titan
Amicus Therapeutics (FOLD) CEO disposes 1.0M shares, options in BioMarin merger - Stock Titan
BioMarin completes $4.8B acquisition of Amicus Therapeutics - Investing.com UK
Amicus Therapeutics Q3 2025 Earnings Preview - MSN
[POS AM] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) taken private in $14.50-per-share cash merger - Stock Titan
[POSASR] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics - marketscreener.com
BioMarin completes $4.8B acquisition of Amicus Therapeutics By Investing.com - Investing.com South Africa
Amicus Therapeutics withdraws Nasdaq listing | FOLD SEC FilingForm 25-NSE - Stock Titan
BioMarin Completes Amicus Acquisition, Expands Rare Disease Portfolio - TipRanks
BioMarin (NASDAQ: BMRN) adds Galafold and Pombiliti in Amicus deal - Stock Titan
BioMarin Completes Acquisition of Amicus Therapeutics - PR Newswire
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD) - AOL.com
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Composite Index - marketscreener.com
CIBRA Capital Increases Amicus Therapeutics Holdings – April 2026 SEC FilingNews and Statistics - IndexBox
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):